X4 Pharmaceuticals Announces Positive Results from Completed Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN)

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/12/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. CRM
9. MSFT
10. DOL:CN

Go back to X4 Pharmaceuticals Announces Positive Results from Completed Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN)

X4 Pharmaceuticals (XFOR) PT Lowered to $4 at Stifel

November 13, 2024 4:00 PM EST

Stifel analyst Stephen Willey lowered the price target on X4 Pharmaceuticals (NASDAQ: XFOR) to $4.00 (from $5.00) while maintaining a Buy rating.

The analyst comments "The XOLREMDI launch in WHIM syndrome was always going to be a show-me story for investors and the longer-term opportunity... More